BG505 SOSIP.664 gp140 vaccine
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for BG505 SOSIP.664 gp140 vaccine, covering 2024-06-11 to 2024-06-11. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Evaluate the Safety and Immunogenicity of 2 Doses of 100µg BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, Given to a Population of Adults Who Have Received 3 Doses of 300µg BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted [Phase 1]